Today's issue of FiercePharma covered two interesting FDA decisions (or non- decisions, if you prefer). The first involves the FDA's decision not to approve generic versions of Purdue's Oxycontin:…
Rob Wright has a really good article on preparing for BIO. In fact, it's applicable for just about any major conference or convention. You can read the entire…
Very interesting point made by Ranjit Shahani from Novartis India: The immense talents in India's pharmaceutical companies should be focused on R&D of medicines that will help the people…
At Lacerta Bio, we've been reading the fascinating book, The Signal and The Noise by Nate Silver. The book is a terrific review of how and why forecasts often fail,…
The always excellent Bruce Booth wrote a good summary of the key Preclinical deals we've seen so far this year. The post is available here. Some of his broader questions are especially…
As BD consultants, we attend a number of conferences, both large and small. Some have one-on-one meetings, some don't. Some are scientific conferences, while others are focused on partnering. As…
Today we learn that generics giant Mylan has entered into a partnership with India-based Biocon to focus on insulin analog biosimilars: Under the terms of this collaboration, Mylan will have…
The announcement of the Allergan acquisition of MAP Pharmaceuticals for nearly $1 billion (and the NuPathe approval) is a good reminder of the potential value (both clinical and financial) of reformulation and drug…
Lacerta Bio, along with approximately 10,000 other life science investors, executives, consultants, service providers, hangers-on, and many others, congregated in San Francisco for a variety of conferences, including the JP…
Happy New Year! For many companies, 2012 was a challenging year. How will 2013 play out? Here are a few ideas we've discussed internally as we look forward to 2013:…